Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Age-adapted immunosuppression after kidney transplantation in elderly recipients
NL-OMON48113Phase 3Completed
- Sponsor
- University Medical Center Groningen
- Start
- Jul 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tacrolimus, everolimus, mycophenolate mofetil, basiliximab and prednisolone in kidney failure and kidney transplant (2 arms), sponsored by University Medical Center Groningen. Primary endpoints: Successful transplantation in stratum A at 1 year and Successful transplantation in stratum B at 1 year. Started Jul 2019; status: completed.
02
Drugs
tacrolimuseverolimusmycophenolate mofetilbasiliximabprednisolone
03
Conditions
kidney failurekidney transplant
Beyond the preview
Go deeper on NL-OMON48113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48113.